REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
07/06/2026
Back to search
Official data from USPTO
LUNAC
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
LUNAC
ST13
US500000079289877Class
5, 40, 42
Filing
79289877
Registration
6405774
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
32
Latest update
07/06/2026
Trademark type
Word
Nice classes
5, 40, 42
Filing date
01/27/2020
Registration date
07/06/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/06/2021
Last transaction
07/06/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
GB
Examiner
TRATOS, MARK STEVEN
Law office
M40
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Lunac Therapeutics Limited
Representatives
Matthew L. Frisbee Leason Ellis LLP
Technical classification
Nice Classes
Class 5Class 40Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Medical and veterinary preparationsnamely pharmaceutical preparations for the treatment of blood disordersblood clots and to prevent blood coagulation; pharmaceuticalsnamely pharmaceutical preparations for the treatment of blood disordersblood clots and to prevent blood coagulation; medicinesnamely pharmaceutical preparations for the treatment of blood disorders; therapeutic medicines and pharmaceuticalsnamely pharmaceutical preparations for the treatment of blood disorders; medical diagnostic productsnamely diagnostic preparations for medical purposes; anticoagulants; anticoagulants for the treatment of medical conditions; anticoagulants for the treatment of thrombosis and blood clots; anticoagulants for use in the discoverypreclinical and clinical development of therapeutic products and medical diagnostic products; medicines and pharmaceuticals for use in the discoverypreclinical and clinical development of therapeutic products and medical diagnostic productsnamely anticoagulants
Class 40
custom manufacture of chemicalsmedicinespharmaceuticals and anticoagulants; custom manufacture of therapeutic products and medical diagnostic products in the nature of pharmaceuticals for the treatment of blood disordersblood clots and to prevent blood coagulation; consultancyadvisory and information in connection with all of the aforementioned servicesproviding advisory services regarding the custom manufacture of pharmaceuticals for others
Class 42
Scientific and technological servicesproviding scientific research for medical purposes in the field of blood disordersblood clots and to prevent blood coagulation; research and design in relation to sciencetechnologypharmaceuticalsmedicinebloodthrombosis and anticoagulantsproviding scientific research for medical purposes in the field of blood disordersblood clots and to prevent blood coagulation; preparation of scientific reports on anticoagulants for medical and veterinary purposes; engineering of medicines and pharmaceuticals; bimolecular engineering of anticoagulantsthe manipulation of oral small molecules for use as anticoagulants; engineering of anticoagulants; engineering of medicines and pharmaceuticals for the treatment of thrombosis and blood clotting; scientific services relating to the discoverypreclinical and clinical development of therapeutic and medical diagnostic productsproviding scientific research for medical purposes in the field of blood disordersblood clots and to prevent blood coagulation; consultancyadvisory and information in connection with all of the aforementioned servicesadvising regarding scientific research for medical purposes in the field of blood disordersblood clots and to prevent blood coagulation
Publications
History of USPTO decisions and trademark events.
32 publications found
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
06/17/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
06/17/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
06/17/2025
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
11/29/2021
FICS
FINAL DISPOSITION NOTICE SENT TO IB
11/09/2021
FIMP
FINAL DISPOSITION PROCESSED
11/09/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
10/06/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
07/06/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/20/2021
PUBO
PUBLISHED FOR OPPOSITION
04/20/2021
GPNX
NOTIFICATION PROCESSED BY IB
04/18/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
03/31/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
03/31/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/31/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/12/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
03/11/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
03/11/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
03/11/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
03/11/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/25/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/24/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/24/2021
RFNT
REFUSAL PROCESSED BY IB
09/27/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
09/06/2020
RFRR
REFUSAL PROCESSED BY MPU
09/02/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
07/28/2020
MAFR
APPLICATION FILING RECEIPT MAILED
07/28/2020
CNRT
NON-FINAL ACTION WRITTEN
07/27/2020
DOCK
ASSIGNED TO EXAMINER
07/24/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/24/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
07/23/2020
Continuous trademark protection
Get notified about every new filing that threatens LUNAC or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.